alexa Albendazole therapy for single small enhancing CT lesions (SSECTL) in the brain in epilepsy.
Neurology

Neurology

International Journal of Neurorehabilitation

Author(s): Thussu A, Chattopadhyay A, Sawhney IM, Khandelwal N

Abstract Share this page

Abstract BACKGROUND: Single small enhancing CT lesions (SSECTL) of the brain with or without perifocal oedema are common in patients with symptomatic epilepsy in India. Solitary cysticercus granuloma, a benign form of parenchymal neurocysticercosis, is considered to be the most common aetiology for SSECTL. Definite information is lacking regarding the effectiveness of antiparasitic treatment on resolution of these lesions and on long term seizure recurrence. OBJECTIVE: To evaluate the response to albendazole treatment in patients who had SSECTL and new onset seizures treated with antiepileptic drugs (AED) in a prospective clinical trial. METHODS: 43 patients who presented with new onset seizures and were documented to have SSECTL were alternatively allocated to receive albendazole 15 mg/kg/day for 2 weeks or no cysticidal therapy. All patients were treated with AED and followed for at least 6 months for seizure recurrence, and serial CT scans were obtained at 4 weeks, 3 months and at study completion. RESULTS: 28 (65\%) patients were aged 5-25 years and 31 (72\%) presented clinically with partial motor seizures with or without generalisation. Most of the SSECTL were ring lesions (75\%) and located in and around the sensory-motor cortex at the gray-white junction (65\%). In the albendazole group, 56\% of patients compared with 35\% in the control group showed resolution of SSECTL (p = 0.154) at 1 month. 22 of 23 patients (95.6\%), who received albendazole, compared with 14 of 20 patients (70\%) in the control group, demonstrated radiological resolution on study completion (p = 0.03). Punctate residual calcification and seizure recurrence were observed in four patients (9.3\%) in the control group and in three (7\%) patients in the albendazole group (p = 0.47). CONCLUSIONS: In patients presenting with seizures due to single viable parenchymal neurocysticercosis, albendazole hastens the resolution of SSECTL if treatment is given in the early phase of the illness. This article was published in J Neurol Neurosurg Psychiatry and referenced in International Journal of Neurorehabilitation

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords